Autologous Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium Cell Transplantation: Phase 1/2 Clinical Trial for Dry Age-Related Macular Degeneration Commences
Clinical Design and Objectives
This study is a simultaneous Phase 1 and Phase 2 trial, evaluating the safety of transplanting retinal pigment epithelium (RPE) cells derived from autologous induced pluripotent stem cells (iPSCs) in patients aged 55 and older with dry age-related macular degeneration (geographic atrophy). The primary objective is to confirm the safety of intraocular cell transplantation, with long-term efficacy to be verified in subsequent studies.
Mechanism of Action
iPSC-derived RPE cells are created by reprogramming the patient's own cells, reducing the risk of immune rejection while supporting the damaged retina. Dry age-related macular degeneration currently lacks effective treatments beyond nutritional supplements, and cell therapy is expected to be a novel regenerative approach.
Clinical Procedure
Participants undergo a screening process that includes medical history review, physical examination, blood and urine tests, fundus examination, ocular photography, fluorescein angiography, and electroretinography. After screening, local anesthesia is administered to the eye, and iPSC-RPE cells are transplanted.
Expected Outcomes and Risks
The primary objective is to confirm safety, with the potential for vision maintenance or improvement upon success. However, uncertainties remain regarding surgical risks, the use of immunosuppressants, and the long-term survival of transplanted cells.
This clinical trial provides an opportunity to enter the high-value ophthalmic biologics market by initially verifying the safety of iPSC-based cell therapy. It is expected to expand the demand for research and development personnel in the ophthalmology and cell therapy fields, and clinical operation experience will be an important career asset.
Source: ClinicalTrials.gov (api_ct)